Pluristyx, Inc., a leading provider of induced pluripotent stem cell (iPSC)-based technologies, and Solesis, a leader in applied biomaterial solutions including transfection technologies, today ...

Leading GMP cell therapy CDMO I Peace, Inc. ( specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it has successfully generated human induced ...

Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response ...

bit.bio's ioSensory Neurons pain research was selected for presentation at SfN’s Neuroscience 2024 press conference, and it was chosen from over 10,500+ submissions. bit.bio will host an expert panel ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...

While current clinical trials for cardiac regeneration using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) ...

LONDON, Ontario, May 17, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine ...

WOBURN, Mass., Sept. 29, 2025 /PRNewswire/ -- Cell X Technologies today announced a collaboration with BioLamina to integrate BioLamina's defined laminin reagents (Biolaminin®) with Cell X's ...